Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
BMI OrganBank Secures FDA Breakthrough Device Designation for Innovative Kidney Transplant Technology

From PR Newswire

By

August 4, 2025

BMI OrganBank Secures FDA Breakthrough Device Designation for Innovative Kidney Transplant Technology

BMI OrganBank Secures FDA Breakthrough Device Designation for Innovative Kidney Transplant Technology
WINSTON-SALEM, N.C., Aug. 04, 2025 /PRNewswire/ -- BMI OrganBank, a pioneering leader in organ assessment and preservation, proudly announces that its revolutionary organ preservation device has received the prestigious Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This designation, granted for their kidney preservation device, underscores BMI OrganBank's commitment to advancing transformative technologies that will significantly improve outcomes for transplant patients. With current kidney perfusion technologies, which use cold storage temperatures, it is difficult to evaluate the function of kidneys before transplant. Furthermore, they are vulnerable to significant injury during the storage period before transplantation. As such, a large proportion of donated kidneys remain unused. BMI OrganBank's groundbreaking room temperature machine perfusion (RTMP) platform, developed in collaboration with leading transplant surgeons and academic medical centers, shows great promise to facilitate kidney quality assessment and extend preservation times. BMI OrganBank intends to increase the number of kidneys available for transplant and address stubbornly long kidney transplant waitlist times. A clinical study is planned for early next year. "We are incredibly honored to receive this significant designation from the FDA and look forward to working with them as we prepare for clinical studies" stated Carrie DiMarzio, Chief Executive Officer and Co-Founder.

View original article on prnewswire.com

Most Recent

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

The de-extinction startup is looking to double or triple its previous valuation, according to the report.

Jul 20, 2026

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

The one-year-old startup aims to reinvent financial architecture for autonomous AI transactions.

Jul 20, 2026

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

AI infrastructure company Infinity announced Monday a $15 million raise at a $100 million valuation from investors including Touring Capital, Principal VC, and researchers from companies such as OpenAI and Anthropic.

Jul 20, 2026

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

For the first time since 2024, StrictlyVC is coming back to New York City — and we're bringing the kind of access you’d expect from an under-wraps event to the whole startup, VC, and dealmaking community.

Jul 20, 2026

Similar Posts

National Kidney Foundation's Innovation Fund Invests in BMI OrganBank to Advance Breakthrough Kidney Transplant Technology

National Kidney Foundation's Innovation Fund Invests in BMI OrganBank to Advance Breakthrough Kidney Transplant Technology

National Kidney Foundation's Innovation Fund invests in BMI OrganBank to advance breakthrough kidney transplant technology.

Jul 14, 2025

BMI OrganBank Announces Head-to-Head Preclinical Data for OrganBank Kidney Platform

BMI OrganBank Announces Head-to-Head Preclinical Data for OrganBank Kidney Platform

BMI OrganBank presents head-to-head preclinical data showing OrganBank Kidney platform outperforms cold storage methods.

Apr 21, 2026

BMI OrganBank Secures $3.5 Million NIH Grant to Advance Innovative Kidney Preservation Technology Towards Clinical Trials

BMI OrganBank Secures $3.5 Million NIH Grant to Advance Innovative Kidney Preservation Technology Towards Clinical Trials

BMI OrganBank receives $3.5M NIH grant to advance kidney preservation technology towards clinical trials.

Feb 12, 2025

BMI OrganBank, Atrium Health and LifeShare Carolinas Partner to Launch Nation's First Organ Banking Technology

BMI OrganBank, Atrium Health and LifeShare Carolinas Partner to Launch Nation's First Organ Banking Technology

BMI OrganBank partners with Atrium Health and LifeShare Carolinas to launch nation's first organ banking technology.

Mar 9, 2025

Most Recent

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

The de-extinction startup is looking to double or triple its previous valuation, according to the report.

Jul 20, 2026

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

The one-year-old startup aims to reinvent financial architecture for autonomous AI transactions.

Jul 20, 2026

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

AI infrastructure company Infinity announced Monday a $15 million raise at a $100 million valuation from investors including Touring Capital, Principal VC, and researchers from companies such as OpenAI and Anthropic.

Jul 20, 2026

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

For the first time since 2024, StrictlyVC is coming back to New York City — and we're bringing the kind of access you’d expect from an under-wraps event to the whole startup, VC, and dealmaking community.

Jul 20, 2026

Similar Posts

National Kidney Foundation's Innovation Fund Invests in BMI OrganBank to Advance Breakthrough Kidney Transplant Technology

National Kidney Foundation's Innovation Fund Invests in BMI OrganBank to Advance Breakthrough Kidney Transplant Technology

National Kidney Foundation's Innovation Fund invests in BMI OrganBank to advance breakthrough kidney transplant technology.

Jul 14, 2025

BMI OrganBank Announces Head-to-Head Preclinical Data for OrganBank Kidney Platform

BMI OrganBank Announces Head-to-Head Preclinical Data for OrganBank Kidney Platform

BMI OrganBank presents head-to-head preclinical data showing OrganBank Kidney platform outperforms cold storage methods.

Apr 21, 2026

BMI OrganBank Secures $3.5 Million NIH Grant to Advance Innovative Kidney Preservation Technology Towards Clinical Trials

BMI OrganBank Secures $3.5 Million NIH Grant to Advance Innovative Kidney Preservation Technology Towards Clinical Trials

BMI OrganBank receives $3.5M NIH grant to advance kidney preservation technology towards clinical trials.

Feb 12, 2025

BMI OrganBank, Atrium Health and LifeShare Carolinas Partner to Launch Nation's First Organ Banking Technology

BMI OrganBank, Atrium Health and LifeShare Carolinas Partner to Launch Nation's First Organ Banking Technology

BMI OrganBank partners with Atrium Health and LifeShare Carolinas to launch nation's first organ banking technology.

Mar 9, 2025